MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,394M
Net Income
-$14M
Net Profit Margin
-1.00%
EPS
-$0.04
Unit: Million (M) dollars
Revenue Breakdown
Device Products
Overthe Counter Products
Pharmaceutical Products
Others
Revenue Breakdown
Product
Product And Service Other
Revenue Breakdown
Vision Care
Pharmaceuticals
Surgical
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
1,394
1,244
1,405
1,281
Cost of goods sold (excluding amortization and impairments of intangible assets) and cost of other revenues-Product
527
482
533*
509
Cost of goods sold (excluding amortization and impairments of intangible assets) and cost of other revenues-Product And Service Other
0
1
1*
1
Selling, general and administrative (note 4)
588
544
564
528
Research and development
114
101
94
95
Amortization of intangible assets
57
57
56
68
Other expense, net
-25
-26
-46
15
Total expenses
1,311
1,211
1,293
1,186
Operating income (loss)
83
33
112
95
Interest income
4
4
3
3
Interest expense
93
97
98
101
Gain on extinguishment of debt
0
-1
0
3
Foreign exchange and other
-5
-3
-4
-3
Gain before provision for income taxes
-11
-64
13
-3
Expected provision for income taxes at canadian statutory rate
-
-
43*
-
Domestic provincial and local income taxes, net of federal (national) income tax effect
-
-
0*
-
Foreign tax rate differences-US
-
-
-1*
-
Effects of cross-border taxes-US
-
-
1*
-
Research & development tax credits-US
-
-
2*
-
Contingent consideration fair value adjustments-US
-
-
-1*
-
Intercompany profit in ending inventory-US
-
-
1*
-
Other-US
-
-
1*
-
Foreign tax rate differences-IE
-
-
12*
-
Change in valuation allowance-IE
-
-
3*
-
Disallowed interest-IE
-
-
4*
-
Capital loss on sale of assets-IE
-
-
-2*
-
Foreign exchange impact-IE
-
-
1*
-
Intercompany profit in ending inventory-IE
-
-
-4*
-
Other-IE
-
-
0*
-
Change in valuation allowance-NL
-
-
1*
-
Other-NL
-
-
0*
-
Foreign tax rate differences-DE
-
-
-2*
-
Other-DE
-
-
1*
-
Foreign tax rate differences-Foreign Tax Jurisdiction Other
-
-
2*
-
Effect of changes in tax laws or rates enacted in the current period
-
-
0*
-
Effects of cross-border taxes-CA
-
-
1*
-
Tax credits
-
-
0*
-
Change in valuation allowance-CA
-
-
4*
-
Non-deductible amount of share-based compensation
-
-
4*
-
Disallowed interest-CA
-
-
1*
-
Change in uncertain tax positions
-
-
0*
-
Foreign exchange impact-CA
-
-
6*
-
Other-CA
-
-
0*
-
Benefit from (provision for) income taxes
-1
6
71
22
Net loss
-10
-70
-58
-25
Net income attributable to noncontrolling interest
4
1
0
3
Net loss attributable to bausch + lomb corporation
-14
-71
-58
-28
Basic EPS
-0.04
-0.2
-0.164
-0.08
Diluted EPS
-0.04
-0.2
-0.164
-0.08
Basic Average Shares
357,100,000
355,200,000
354,500,000
354,200,000
Diluted Average Shares
357,100,000
355,200,000
354,500,000
354,200,000
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
Vision Care
$270M
(-64.14%↓ Y/Y)
Surgical
$254M
(17.59%↑ Y/Y)
Revenue From Contract
With Customer...
$497M
Pharmaceuticals
$299M
(-3.24%↓ Y/Y)
Vision Care
$1M
(-99.87%↓ Y/Y)
Pharmaceuticals
$55M
(-82.20%↓ Y/Y)
Vision Care
$13M
(-98.27%↓ Y/Y)
Vision Care
$3M
(-99.60%↓ Y/Y)
Surgical
$2M
(-99.07%↓ Y/Y)
Net loss
attributable to bausch + lomb...
-$14M
(77.42%↑ Y/Y)
Device Products
$524M
Overthe Counter
Products
$497M
Pharmaceutical Products
$300M
Brandedand Other Generic
Products
$68M
Other Revenues
$5M
Net loss
-$10M
(82.76%↑ Y/Y)
Net income
attributable to...
$4M
(0.00%↑ Y/Y)
Benefit from (provision
for) income taxes
-$1M
(98.88%↑ Y/Y)
Total revenues
$1,394M
(9.08%↑ Y/Y)
Gain before
provision for income taxes
-$11M
(92.52%↑ Y/Y)
Operating income (loss)
$83M
(854.55%↑ Y/Y)
Interest income
$4M
(33.33%↑ Y/Y)
Total expenses
$1,311M
(1.71%↑ Y/Y)
Interest expense
$93M
(-27.34%↓ Y/Y)
Foreign exchange and
other
-$5M
(-150.00%↓ Y/Y)
Selling, general and
administrative (note 4)
$588M
(1.55%↑ Y/Y)
Cost of goods sold
(excluding amortization...
$527M
(0.76%↑ Y/Y)
Research and development
$114M
(18.75%↑ Y/Y)
Amortization of intangible
assets
$57M
(-14.93%↓ Y/Y)
Other expense, net
-$25M
(-13.64%↓ Y/Y)
Buy us a coffee
Bausch & Lomb Corp (BLCO)
Bausch & Lomb Corp (BLCO)